PrognosDx, Accium team on histone biomarker tests

PrognosDx Health is combining its epigenetics technology with Accium BioSciences' accelerator mass spectronomy platform to develop predictive histone biomarker tests. The two companies hope to create tools that will help clinicians treat cancer. “We have identified specific studies that would help further define the developmental direction of various diagnostic tests and the potential benefits they may provide to specific patient populations," noted Accium president Ali Arjomand in a Genetic Engineering News report. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.